The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1221
November 7, 2005
View Complete Issue         Table of Contents 2019 
Ramelteon (Rozerem) for Insomnia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ramelteon (Rozerem) for Insomnia
November 7, 2005 (Issue: 1221)
Ramelteon (Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ramelteon (Rozerem) for Insomnia
Article code: 1221a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.